SCHEMBL257528

SCHEMBL257528

Cc1cccc(C(=O)Cc2ccccc2)c1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 2/20 0.45
USP2 O75604 1/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
ERCC5 P28715 1/20 0.44
FEN1 P39748 1/20 0.44
FFAR1 O14842 1/20 0.43
P2RX7 Q99572 2/20 0.43
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
AKR1B1 P15121 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515738 0.84 SMN1; SMN2 (0.60) SMN1; SMN2GAAL3MBTL1LMNAUSP2
SCHEMBL30394799 0.84 SMN1; SMN2 (0.60) SMN1; SMN2GAAL3MBTL1LMNAUSP2
SCHEMBL8984584 0.83 ERCC5 (0.60) GAAMAPTL3MBTL1USP2TP53
SCHEMBL3468225 0.83 SMN1; SMN2 (0.51) SMN1; SMN2GAAL3MBTL1LMNAUSP2
SCHEMBL3278890 0.80 SMN1; SMN2 (0.49) SMN1; SMN2GAALMNAUSP2TP53
SCHEMBL15197234 0.79 SMN1; SMN2 (0.48) SMN1; SMN2GAAMAPTLMNAUSP2
SCHEMBL7129795 0.78 MEN1 (0.62) MAPTL3MBTL1LMNAUSP2TP53
SCHEMBL1515732 0.77 ERCC5 (0.59) MAPTL3MBTL1LMNAUSP2TP53
SCHEMBL11503697 0.76 CTSS (0.46) GAAMAPTL3MBTL1LMNAP2RX7
SCHEMBL306828 0.76 TSHR (0.63) MAPTLMNAUSP2HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 SMN1; SMN2 2704/4885GAA 4354/4885MAPT 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.